Credits: Canva
Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.
Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".
In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.
Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.
Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.
The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.
Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.
Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.
Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.
Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.
However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.
Credit: Mark Kelly/X
Actress Olivia Munn has joined US Senator Mark Kelly to push for legislation that would make breast cancer risk assessments a routine part of healthcare for American women, helping them understand their individual risk and access appropriate screening.
Together, they have introduced the Know Your Risk Act, which aims to expand access to validated breast cancer risk assessment tools and integrate them into routine healthcare.
Munn, who was diagnosed with breast cancer in 2023, said a risk assessment prompted her doctor to recommend further testing despite her having a normal mammogram and negative genetic testing. The additional tests detected an aggressive cancer early.
"Had it not been for that assessment, my breast cancer may not have been identified when it was," Munn said while announcing the legislation alongside Kelly.
Also read: World Breast Cancer Day 2026: Life After Breast Cancer, The Fear No One Sees
Announcing the legislation outside the US Capitol, Kelly said existing breast cancer risk assessment tools are not being used widely enough, leaving many women unaware of their individual risk.
"These tools already exist, but too often doctors aren't using them and women don't know that they're available," Kelly said.
The Democratic senator from Arizona said the Act would make breast cancer risk assessments a routine part of healthcare, helping women and their doctors understand individual risk and determine appropriate screening.
"Women shouldn't have to ask for these assessments. They should be part of regular care like getting a blood pressure reading taken," Kelly said.
He added that the legislation had bipartisan support, with lawmakers recognizing the importance of expanding access to early detection.
Munn's experience highlights why individual risk assessments matter, particularly when standard screening and genetic testing may not identify a woman's breast cancer risk.
Despite having a normal mammogram and negative genetic testing, her risk assessment prompted further investigations that led to her diagnosis.
She said the experience motivated her to work with Kelly to ensure other women have access to similar assessments.
According to the World Health Organization (WHO), breast cancer caused an estimated 694,000 deaths worldwide in 2024. It was the most commonly diagnosed cancer among women in 164 of 186 countries.
In the US, breast cancer is the second leading cause of cancer death among women, according to the Centers for Disease Control and Prevention (CDC).
Early detection can significantly improve breast cancer outcomes. According to the National Cancer Institute, the five-year relative survival rate for women with localized breast cancer is more than 99%.
During the announcement, a representative of breast cancer organization Susan G. Komen highlighted the difference between detecting the disease before and after it spreads, noting that survival rates can fall to around 30% when breast cancer is diagnosed at a distant stage.
The representative also pointed to the rising number of diagnoses among women under 50, many of whom may not consider themselves at risk.
The Know Your Risk Act seeks to address this gap by expanding access to validated risk assessment tools, helping women and their doctors better understand individual risk and make informed decisions about screening.
Credit: AI
New rules to govern organ donation in the United States went into effect from Wednesday, November 18, 2026. According to the latest safeguards, before organ recovery can begin, a minimum five-minute observation period is mandatory after a patient's circulation stops.
The rules come amid concerns about patients showing signs of neurological activity during the organ recovery procedure and also whether it had been adequately confirmed that the patient died.
The rules apply to donation after circulatory death (DCD), a process in which organs may be recovered after a patient's heart and circulation have stopped. They are not applicable to every form of organ donation.
The new requirements were developed under the Health Resources and Services Administration (HRSA) and the Organ Procurement and Transplantation Network (OPTN). They include additional safeguards, including stronger and clearer neurological checks, a formal process to pause donation when safety concerns arise, and more transparent communication with families.
The changes come after HRSA probed into organ procurement systems. In July 2025, the US Department of Health and Human Services said it had examined 351 cases in which organ donation had been authorised but ultimately did not proceed.
The review found concerning details in 103 cases, including 73 patients who showed neurological signs that were considered incompatible with organ donation. It also found that at least 28 patients may not have been deceased when organ recovery was initiated.
On a wider front, the investigation sparked questions about the inadequacy of neurological assessments, coordination between hospitals and organ procurement organisations, and the documentation of death. HRSA subsequently directed the OPTN to strengthen safeguards across the donation process.
Also read: Not Everyone With Obesity Is Unhealthy: New Study Challenges BMI
Under the new policy, an observation period of at least five minutes must pass after circulation has ceased before organ recovery can begin.
The aim is to confirm that the heart does not restart spontaneously, a rare phenomenon called autoresuscitation. It is also sometimes called the Lazarus phenomenon.
In DCD, a patient's life-saving treatment is stopped after a decision made by the patient or their legally authorised representative in consultation with the doctors.
If the patient dies after their heart and circulation stop, organ donation may proceed after death has been determined with complete certainty and the mandatory observation period completed.
Also read: Life At Any Cost: Why We Fight To Prolong Life But Question The Idea To Ease Death?
Apart from the five-minute observation period, the new also include:
Credit: AP Photos
After 26 years, the US has lost its measles elimination status, marking a major setback for public health efforts. The resurgence has intensified criticism of Health and Human Services Secretary Robert F. Kennedy Jr. over his vaccine policies and rhetoric.
The Pan American Health Organization (PAHO) confirmed that the US had lost the status it maintained since 2000.
The country has recorded more than 5,700 measles cases and 11 deaths. Pennsylvania, the hardest-hit state, has reported its eighth measles-associated death of 2026.
A CDC-led report identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns.
The actual number may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.
“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.
Decades of MMR vaccination meant many doctors had never encountered measles during their medical careers. However, declining vaccination rates have allowed the disease to spread in under-vaccinated communities.
Criticism of Kennedy has crossed party lines. Republican Senator Bill Cassidy of Louisiana on Sunday criticised what he called a "series of failures" under Kennedy's leadership at the Department of Health and Human Services.
"This has been a failure. If I were president, I would choose someone else because there needs to be accountability for higher health care costs, more measles deaths, losing elimination status, and no progress on processed foods," Cassidy said on CBS News.
Democratic senators Angela Alsobrooks and Patty Murray have also called for Kennedy's removal.
Alsobrooks (Maryland) condemned the loss of measles elimination status and called Kennedy's tenure a disgrace. She had called for his resignation or dismissal in May 2025. Her resolution of disapproval against Kennedy now has 28 Senate co-sponsors.
Senator Richard Blumenthal (Connecticut) has demanded answers over the alleged suppression of a CDC warning about measles risks during pregnancy, while criticising the administration's vaccine policies.
Murray (Washington) has blamed Trump and Kennedy's leadership for the loss of elimination status and repeatedly called for Kennedy's removal.
Read More: What Happens After Measles Infection? The Hidden Risks That Can Last For Years
Democratic governors have also blamed Kennedy for the setback. New York Governor Kathy Hochul said the loss of measles elimination status contradicted Kennedy's promise to make America healthy again.
"RFK Jr. promised to 'Make America Healthy Again.' Now America has lost its measles-free status for the first time in 26 years," Hochul said.
"A disgraceful display of incompetence from the nation's highest public health office," she added.
Pennsylvania Governor Josh Shapiro blamed vaccine misinformation and skepticism for the setback. "There is a clear line from the misinformation, vaccine skepticism, and incompetence of RFK Jr. to this devastating news and very real consequences," Shapiro said.
Kentucky Governor Andy Beshear explicitly demanded Kennedy's removal. "This dangerous setback was 100% avoidable and is the result of one person: RFK Jr.," Beshear said. "Remove him now."
An HHS spokesperson rejected the governors' criticism in a statement to Fox News Digital, calling their attacks "baseless" and arguing that declining vaccination rates predated the Trump administration.
The spokesperson said the administration remained focused on expanding vaccine access, closing immunisation gaps and assisting state and local officials with outbreak investigations.
Kennedy has vowed to stop measles outbreaks and restore the country's elimination status while continuing to recommend vaccination.
"We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status," Kennedy said in a statement.
"I continue to recommend MMR vaccination as the most effective way to prevent measles," he added.
© $2026 Times Horizon Private Limited